Search PubMed⌕ Search

Biomedical subjects

J Bell

Publications and source records attributed to J Bell.

482 records · Page 27Linked to original sources
PubMedDate not supplied

Immunocytochemical studies of the distribution of alpha and pi isoforms of glutathione S-transferase in cystic renal diseases.

We describe immunohistochemical studies of the expression of alpha and pi class glutathione S-transferases (GSTs) in normal fetal kidneys. These define, in greater detail, changes in expression of alpha isoforms in the proximal tubule. At about 36 weeks of gestation expression of alpha isoforms was down-regulated in the distal tubules and collecting ducts while pi was expressed throughout the nephron. Tubular expression of alpha isoforms was restricted to the part adjacent to the glomerulus; cells farthest from the glomerulus were negative. After 40 weeks of gestation, alpha isoforms were expressed along the entire proximal tubule, while pi was restricted to the distal tubule and collecting ducts. GST expression was also studied in multicystic renal dysplasia, autosomal recessive polycystic kidney disease, and autosomal dominant polycystic kidney disease to determine whether the patterns of expression of alpha and pi isoforms allow identification of the origin of the cysts that characterize these diseases. Cysts were lined by epithelia that were strongly positive for alpha and pi isoforms. The epithelia of noncystic nephrons in renal cystic dysplasia demonstrated delayed maturity, suggesting that GST expression was dependent on the stage of development and not length of gestation.

Epithelium↗
PubMedDate not supplied

The happy wanderer.

Explore the source record for details and available documents.

Aged↗
PubMedDate not supplied

Further evidence for different isoenzymic forms of a cell surface protease, guanidinobenzoatase, associated with tumours.

Normal colonic epithelial cells possess a cell surface protease referred to as guanidinobenzoatase (GB) and a corresponding cytoplasmic protein inhibitor of GB. Colonic carcinoma cells possess two isoenzymic forms of GB, the normal and the carcinoma specific form, each of which is recognised by the corresponding inhibitors present in the cytoplasm of colonic carcinoma cells. An affinity-purified inhibitor preparation obtained from the cytoplasm of cultured colonic carcinoma cells inhibited these two colonic carcinoma isoenzymic forms of GB but not the GB associated with other forms of tumour. The data suggest that each cell type possessing isoenzymic forms of cell surface GB also possesses the corresponding cell-specific inhibitors of GB.

Carboxylic Ester Hydrolases↗
PubMedDate not supplied

Fluorescent location of tumour cells in fine needle aspirates.

Cells obtained by fine needle aspiration of breast lumps were spread onto microscope slides, defatted with xylene and stained with a fluorescent probe for a cell surface protease. In these aspirates, carcinoma cells possess an active cell surface protease, guanidinobenzoatase (GB), very similar to plasminogen activator (1), which binds the fluorescent probe as a competitive inhibitor. Cells obtained from benign and normal breast lack this active GB and can be distinguished easily from the carcinoma cells by fluorescent microscopy. We use this simple technique to examine breast lumps containing carcinoma cells and to demonstrate the similarity of GB on these carcinoma cells to tissue type plasminogen activator (t-PA).

Aminoacridines↗
PubMedDate not supplied

Treatment of intracranial aneurysms with preservation of the parent vessel: results of percutaneous balloon embolization in 84 patients.

Treatment of intracranial arterial aneurysms by interventional neurovascular techniques is now being performed in selected cases. From a transfemoral approach, under local anesthesia, a detachable silicone microballoon can be guided through the intracranial circulation, directed into the aneurysm, inflated with a polymerizing agent for solidification, and detached. The goal is to exclude the aneurysm from the circulation and preserve flow through the parent artery. Since 1984, 84 patients have been treated by this technique. The patients ranged in age from 15 to 83 years (mean age, 48) and included 63 females and 21 males. The distribution of aneurysms included 59 in the anterior circulation and 25 in the posterior circulation. The presenting symptom or cause was mass effect in 45 patients (53.6%), subarachnoid hemorrhage in 31 patients (36.9%), carotid-cavernous sinus fistula resulting from rupture of an intracavernous aneurysm in six cases (7.1%), trauma in one case, and transient cerebral ischemia due to emboli in one case. Permanent complications directly related to therapy included 15 deaths and nine cases of stroke. Clinical and radiologic follow-ups were performed 1, 3, and 12 months after treatment; duration of follow-up ranged from 3 to 68 months (mean, 35.5 months). In 65 cases (77.4%) there was evidence of complete aneurysmal occlusion, and in 19 cases 922.6%) there was subtotal occlusion greater than 85%. Interventional techniques for treatment of intracranial aneurysms may be useful as a therapeutic alternative in those patients not amenable to standard surgical therapy.

Adolescent↗
PubMedDate not supplied

New microballoon device for transluminal angioplasty of intracranial arterial vasospasm.

A new microballoon device has been developed to treat intracranial arterial vasospasm by transluminal angioplasty. The balloon is composed of a unique silicone elastomer that will elongate and conform to the blood vessel lumen, thereby decreasing the risk of vessel rupture. The balloon device, which can be either flow-directed or catheter-guided, is permanently affixed to a 2.0-French microcatheter and introduced from a transfemoral arterial approach. Two balloon sizes are currently available. The smaller-sized balloon, used in most cases, measures 0.85 x 3.50 mm uninflated, will accept a volume of 0.10 ml, and will expand to 3.5 x 12.5 mm. The larger balloon, used in six of 14 cases, measures 1.5 x 3.9 mm uninflated, accepts a volume of 0.50 ml, and expands to 7.5 x 13.5 mm. In clinical trials, this device has been successful in dilating both focal and diffuse areas of vasospasm in multiple territories. Thus far, 40 vascular territories have been successfully treated in 14 patients 15-73 years old. In each case, there was angiographic evidence of successful dilatation, and in 10 patients (71%), clinical improvement in the neurologic condition. Transluminal angioplasty techniques may be useful for reversing some of the serious neurologic sequelae associated with acute intracranial arterial vasospasm.

Angioplasty, Balloon↗